Pharmacology News and Research

Latest Pharmacology News and Research

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.

27 Oct 2009

NCI funds new Center on Microenvironment and Metastasis to research on cancer

Adding potent research firepower and fresh physical perspectives to combat cancer, the National Cancer Institute (NCI) has funded the new Center on the Microenvironment and Metastasis, which will be headquartered at Cornell University.

27 Oct 2009

Pittsburgh Technical Institute gets initial approval for its Practical Nursing program

Pittsburgh Technical Institute (PTI) announces initial approval of its Practical Nursing program by the Pennsylvania State Board of Nursing. At its Monday, September 28, 2009, meeting, the Nursing Board granted PTI permission to offer a 12-month certificate in Practical Nursing through the career college's School of Healthcare.

24 Oct 2009

Nutri5, an effective natural product for the relief of menopausal symptoms

Earlier this year, the BBC reported that "HRT - Hormone Replacement Therapy - can shrink women's brains"1, after a study was published which showed that brain volume in women taking HRT was smaller in two key areas involved in thinking and memory.

23 Oct 2009

Adult male monkeys exposed to cocaine while in the womb have poor impulse control

Adult male monkeys exposed to cocaine while in the womb have poor impulse control and may be more vulnerable to drug abuse than female monkeys, even a decade or more after the exposure, according to a new study by researchers at Wake Forest University School of Medicine. The findings could lead to a better understanding of human drug abuse.

23 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Newcardio expert to present clinical validation data of Phase I and TQT studies on ECG

NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dr. Sam George, NewCardio's Senior Consultant, will join a distinguished roster of speakers, moderators and panelists at the Cardiac Safety Research Consortium (CSRC) annual meeting in Maryland at the Marriot Bethesda, Pooks Hill location on October 29-30, 2009.

23 Oct 2009

CellAura to provide pharmacologically validated reagents for Cisbio Bioassays' cellular studies

CellAura, the leading producer of fluorescence reagents for drug discovery and life sciences research, today announced a development partnership with Cisbio Bioassays. Under the terms of the agreement, CellAura will provide pharmacologically validated reagents to Cisbio Bioassays that will be applied to Cisbio Bioassays’ Tag-lite™ range of non-radioactive assays for cellular studies.

23 Oct 2009

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

Halozyme Therapeutics, Inc. today announced dose response study results that demonstrated faster insulin absorption and increased peak insulin concentrations after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with regular human insulin and with insulin lispro. The enhanced absorption effects were observed at clinically relevant insulin doses across a broad range of PH20 concentrations.

22 Oct 2009

PAREXEL to present key trends in late phase development and Comparative Effectiveness Research

Experts from PAREXEL International Corporation, a leading global biopharmaceutical services provider, will address key trends in late phase development and Comparative Effectiveness Research at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual European Congress, to be held from October 24 - 27, 2009 in Paris, France.

From Parexel 22 Oct 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

FDA uses Wolters Kluwer Pharma Solutions' prescription data for tracking viral treatments

Wolters Kluwer Pharma Solutions, Inc., a leading provider of market data and competitive intelligence to the pharmaceutical and biotech industries, announced today that the Food and Drug Administration (FDA) is using its prescription data to track the treatment of H1N1 and other influenza viruses.

22 Oct 2009

NIH awards $8 million to The Medical College of Wisconsin for heart research

The Medical College of Wisconsin has been awarded a five-year, $8 million, multi-investigator Program Project Grant (PPG) from the National Institutes of Health to understand how human pluripotent stem cells, defined as cells which if left to their own designs can develop into any of the more than 200 cell types in the human body, can be channeled to exclusively become heart muscle cells.

22 Oct 2009

Positive results from KAI Pharmaceuticals' pain therapeutic program

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain.

20 Oct 2009

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Hydra Biosciences today announced that they have entered into an agreement with Cubist Pharmaceuticals, Inc. for a joint collaboration to develop novel ion channel drugs.

20 Oct 2009

Human brains have amazing ability to be energy efficient, say researchers

Our brains, it turns out, are eco-friendly. A study published in Science and reviewed by F1000 Biology members Venkatesh Murthy and Jakob Sorensen reveals that our brains have the amazing ability to be energy efficient.

15 Oct 2009

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

A genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure, according to a new study reported at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

Blocking folic acid action during early pregnancy leads to increased risk of abnormalities in growing baby

Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynaecologists who examined birth and abortion data collected in Israel between 1998 and 2007.

15 Oct 2009

Medications to reduce folic acid during pregnancy increase the risk of abnormalities in fetus

Pregnant women are advised to take vitamin supplements containing folic acid as part of their routine pre-natal care. Now, a new study warns that taking medications that reduce or block the actions of folic acid during the first trimester of pregnancy increase the risk that the growing baby will develop abnormalities.

14 Oct 2009

Pharmacology News and Research

Latest Pharmacology News and Research

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

NCI funds new Center on Microenvironment and Metastasis to research on cancer

Pittsburgh Technical Institute gets initial approval for its Practical Nursing program

Nutri5, an effective natural product for the relief of menopausal symptoms

Adult male monkeys exposed to cocaine while in the womb have poor impulse control

Shire announces new pharmacokinetic data of ADHD medication

Newcardio expert to present clinical validation data of Phase I and TQT studies on ECG

CellAura to provide pharmacologically validated reagents for Cisbio Bioassays' cellular studies

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

PAREXEL to present key trends in late phase development and Comparative Effectiveness Research

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

FDA uses Wolters Kluwer Pharma Solutions' prescription data for tracking viral treatments

NIH awards $8 million to The Medical College of Wisconsin for heart research

Positive results from KAI Pharmaceuticals' pain therapeutic program

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Human brains have amazing ability to be energy efficient, say researchers

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

Blocking folic acid action during early pregnancy leads to increased risk of abnormalities in growing baby

Medications to reduce folic acid during pregnancy increase the risk of abnormalities in fetus

Industry Focus - Biopharma eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Pharmacology News and Research

Latest Pharmacology News and Research

Industry Focus - Biopharma eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in